Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 70.3% in May

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 17,120 shares, a decrease of 70.3% from the May 14th total of 57,617 shares. Based on an average trading volume of 75,265 shares, the short-interest ratio is presently 0.2 days. Currently, 0.4% of the company’s stock are sold short.

Institutional Trading of Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 76.14% of the company’s stock.

Galmed Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ:GLMD traded down $0.00 during midday trading on Friday, reaching $0.61. The company’s stock had a trading volume of 195,023 shares, compared to its average volume of 1,236,955. The firm has a market capitalization of $3.35 million, a PE ratio of -0.49 and a beta of 0.73. Galmed Pharmaceuticals has a twelve month low of $0.41 and a twelve month high of $2.34. The stock has a fifty day moving average of $0.63 and a 200 day moving average of $0.71.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Galmed Pharmaceuticals currently has an average rating of “Sell”.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.